President Trump's planned tariffs for generic drugs are the clearest test yet of whether the administration can keep its promises to both increase U.S. drug manufacturing and lower prescription costs.
Why it matters: Tariffs could give the country more control over the supply chain, but they could also make some of the country's cheapest medicines more expensive at a time when consumers are clamoring for relief.
Challenges with the Medicare Advantage quality rating system are colliding with a broader reckoning over how the federal government pays Medicare Advantage plans.
Why it matters: The five-star rating system, which governs billions of dollars in Medicare Advantage bonus payments, could be ripe for an overhaul as policymakers question how much the privatized Medicare program should cost taxpayers.
